Brokerages forecast that Metacrine, Inc. (NASDAQ:MTCR) will post earnings per share (EPS) of ($0.52) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Metacrine’s earnings. The firm is expected to report its next earnings results on Thursday, June 17th.
On average, analysts expect that Metacrine will report full year earnings of ($2.68) per share for the current fiscal year. For the next fiscal year, analysts anticipate that the business will report earnings of ($3.27) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Metacrine.
A number of research analysts have weighed in on MTCR shares. Royal Bank of Canada reaffirmed a “buy” rating and issued a $25.00 price target on shares of Metacrine in a research note on Sunday, March 21st. Zacks Investment Research lowered shares of Metacrine from a “hold” rating to a “sell” rating in a research note on Tuesday, March 23rd. Finally, Canaccord Genuity reissued a “buy” rating and issued a $19.00 price target on shares of Metacrine in a research note on Monday, March 22nd. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Metacrine presently has an average rating of “Buy” and a consensus price target of $20.67.
Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. bought a new position in Metacrine in the third quarter valued at $906,000. ExodusPoint Capital Management LP acquired a new position in shares of Metacrine during the 3rd quarter worth about $260,000. Deerfield Management Company L.P. Series C bought a new position in shares of Metacrine in the 3rd quarter valued at about $9,469,000. New York State Common Retirement Fund acquired a new stake in shares of Metacrine in the fourth quarter valued at about $56,000. Finally, Wells Fargo & Company MN bought a new stake in Metacrine during the fourth quarter worth about $27,000. 52.31% of the stock is currently owned by institutional investors and hedge funds.
Metacrine, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases. It is developing MET409 that has completed Phase 1b proof-of-concept clinical trial for the treatment of patients with non-alcoholic steatohepatitis (NASH); and is in Phase 2a clinical trial in combination with empagliflozin for the treatment of patients with type 2 diabetes mellitus and NASH.
Recommended Story: G-20
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Metacrine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metacrine and related companies with MarketBeat.com's FREE daily email newsletter.